Planned website maintenance is taking place from 11:00 pm AEDT on Friday 30 October to 6:00 am AEDT on Saturday 31 October 2026. Some pages may be temporarily unavailable. If issues continue outside this time, please contact us.
This webinar will address the recent announcement by the Therapeutic Goods Administration (TGA) that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) in the Poisons Standard for specific conditions when prescribed by a psychiatrist under the Authorised Prescriber scheme.
Background
From 1 July 2023, the TGA will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. They will only be able to be prescribed by authorised psychiatrists who have been approved under the Authorised Prescriber scheme and approved by a Human Research Ethics Committee.
Webinar details
When: Wednesday, 1 March 2023
Where: Online
Time: 4.30pm - 5.30pm AEDT